Physician profile
Derek D Kramer
NPI 1376925388
$4,548.13
in general payments reported to CMS, 2019-2025
21 companies · $833 in 2025
The $833 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $282 · 2021: $479 · 2022: $1,053 · 2023: $641 · 2024: $732 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,205.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $999.25 | 2019-2025 | Cequa, Xelpros |
| Johnson & Johnson Vision Care, INC. | $769.95 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $533.94 | 2019-2025 | Precision 1, Tryptyr, Total30 |
| Coopervision INC. | $385.12 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Biotissue Holdings INC. | $357.72 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $248.58 | 2022-2025 | Xiidra, Infuse, Vyzulta |
| Notal Vision, INC. | $234.26 | 2022 | |
| Novartis Pharmaceuticals Corporation | $176.49 | 2019-2022 | |
| Shire North American Group INC | $137.46 | 2019 | |
| Oyster Point Pharma, INC. | $108.23 | 2022-2023 | Tyrvaya |
| Abbvie INC. | $103.93 | 2022-2024 | |
| Tarsus Pharmaceuticals, INC. | $96.63 | 2024-2025 | Xdemvy |
| Allergan, INC. | $94.79 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $91.83 | 2022 | |
| Abb Con-Cise Optical Group LLC | $54.14 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $52.15 | 2020-2021 | |
| Dompe US, INC. | $31.28 | 2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $24.41 | 2021 | |
| Quidel Corporation | $18.71 | 2019 | |
| Thea Pharma INC. | $15.41 | 2024 | Iyuzeh |
| Oasis Medical, INC. | $13.85 | 2024 | Oasis Tears |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.